Targeting VEGF/VEGFR to Modulate Antitumor Immunity

In addition to the crucial role in promoting the growth of tumor vessels, vascular endothelial growth factor (VEGF) is also immunosuppressive. VEGF can inhibit the function of T cells, increase the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and hinder the differentiation and activation of dendritic cells (DCs). Recent studies have investigated the role of antiangiogenic agents in antitumor immunity, especially in recent 3 years. Therefore, it is necessary to update the role of targeting VEGF/VEGFR in antitumor immunity. In this review, we focus on the latest clinical and preclinical findings on the modulatory role of antiangiogenic agents targeting VEGF/VEGFR in immune cells, including effector T cells, Tregs, MDSCs, DCs, tumor-associated macrophages, and mast cells. Our review will be potentially helpful for the development of combinations of angiogenesis inhibitors with immunological modulators.

[1]  C. Creighton,et al.  VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2 , 2014, Oncogene.

[2]  M. Merchant,et al.  SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI 1 , 2 , 2016 .

[3]  Napoleone Ferrara,et al.  Developmental and pathological angiogenesis. , 2011, Annual review of cell and developmental biology.

[4]  K. Alitalo,et al.  The lymphatic vasculature in disease , 2011, Nature Medicine.

[5]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[6]  I. Holen,et al.  Tumour macrophages as potential targets of bisphosphonates , 2011, Journal of Translational Medicine.

[7]  P. Brossart,et al.  Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. , 2008, Blood.

[8]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[9]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[10]  E. Tartour,et al.  VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.

[11]  V. Georgoulias,et al.  Effect of First‐Line Treatment on Myeloid‐Derived Suppressor Cells' Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Reinhold Förster,et al.  HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes , 2012, Nature Reviews Immunology.

[13]  J. Folkman,et al.  Mast cells and tumor angiogenesis , 1976, International journal of cancer.

[14]  X. Ren,et al.  Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? , 2016, Cancer biology & medicine.

[15]  A. Griffioen,et al.  Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? , 2017, Angiogenesis.

[16]  B. Garmy-Susini,et al.  Integrins in angiogenesis and lymphangiogenesis , 2008, Nature Reviews Cancer.

[17]  D. Carbone,et al.  VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. , 2003, Blood.

[18]  D. Briscoe,et al.  Cutting Edge: Vascular Endothelial Growth Factor-Mediated Signaling in Human CD45RO+ CD4+ T Cells Promotes Akt and ERK Activation and Costimulates IFN-γ Production , 2009, The Journal of Immunology.

[19]  P. Tassone,et al.  Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients , 2016, Cell Death Discovery.

[20]  J. Abastado,et al.  TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression , 2015, Oncotarget.

[21]  M. D. Della Porta,et al.  Dendritic Cells and Vascular Endothelial Growth Factor in Colorectal Cancer: Correlations with Clinicobiological Findings , 2005, Oncology.

[22]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[23]  A. D. Van den Abbeele,et al.  Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.

[24]  H. Okada,et al.  Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy , 2017, Oncogene.

[25]  E. Raymond,et al.  Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST) , 2007, Therapeutics and clinical risk management.

[26]  B. Berk,et al.  Ligand-Independent Activation of Vascular Endothelial Growth Factor Receptor 2 by Fluid Shear Stress Regulates Activation of Endothelial Nitric Oxide Synthase , 2003, Circulation research.

[27]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[28]  K. Aldape,et al.  Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes , 2014, Oncotarget.

[29]  D. Mukhopadhyay,et al.  Vascular Permeability Factor (VPF)/Vascular Endothelial Growth Factor (VEGF) Receptor-1 Down-modulates VPF/VEGF Receptor-2-mediated Endothelial Cell Proliferation, but Not Migration, through Phosphatidylinositol 3-Kinase-dependent Pathways* , 2001, The Journal of Biological Chemistry.

[30]  B. Ruffell,et al.  Dendritic Cells and Cancer Immunity. , 2016, Trends in immunology.

[31]  Clara Alsinet,et al.  VEGF signaling in cancer treatment. , 2014, Current pharmaceutical design.

[32]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[33]  M. May,et al.  Understanding high endothelial venules: Lessons for cancer immunology , 2015, Oncoimmunology.

[34]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[35]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  R K Jain,et al.  Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. , 1998, The Journal of investigative dermatology.

[37]  L. Ellis,et al.  Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. , 2016, Cancer research.

[38]  T. Morisaki,et al.  VEGFR2 is selectively expressed by FOXP3high CD4+ Treg , 2009, European journal of immunology.

[39]  M. Popescu,et al.  Lipoprotein-associated phospholipase A2, myeloperoxidase and vascular endothelial growth factor - predictors of high vascular risk in respiratory bacterial infections , 2016, Journal of medicine and life.

[40]  Chiara Secondini,et al.  Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade , 2017, Oncoimmunology.

[41]  G. Coukos,et al.  Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.

[42]  R. Figlin,et al.  Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.

[43]  R. Jain,et al.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.

[44]  B. Neyns,et al.  Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model , 2015, Oncoimmunology.

[45]  Z. Han,et al.  VEGF-A/Neuropilin 1 Pathway Confers Cancer Stemness via Activating Wnt/β-Catenin Axis in Breast Cancer Cells , 2017, Cellular Physiology and Biochemistry.

[46]  Masafumi Nakamura,et al.  The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. , 2009, Anticancer research.

[47]  C. Divino,et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.

[48]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[49]  J. Villadangos,et al.  Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. , 2004, Blood.

[50]  D. Soto-Pantoja,et al.  CD47 Signaling Regulates the Immunosuppressive Activity of VEGF in T Cells , 2014, The Journal of Immunology.

[51]  I. Melero,et al.  Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium. , 2017, International journal of radiation oncology, biology, physics.

[52]  E. Tartour,et al.  VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. , 2013, Cancer research.

[53]  Antonio Duarte,et al.  Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling , 2012, Nature.

[54]  H. Hurwitz,et al.  The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients , 2008, Cancer Immunology, Immunotherapy.

[55]  David A. Schultz,et al.  A mechanosensory complex that mediates the endothelial cell response to fluid shear stress , 2005, Nature.

[56]  O. Feron,et al.  Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy1 , 2007, The Journal of Immunology.

[57]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[58]  R. Jove,et al.  Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.

[59]  E. Tartour,et al.  Immunomodulatory Activity of VEGF in Cancer. , 2017, International review of cell and molecular biology.

[60]  S. Patel,et al.  The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells , 2016, PloS one.

[61]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[62]  P. Ram,et al.  Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression , 2017, Clinical Cancer Research.

[63]  D. Slaaf,et al.  Tumor angiogenesis factors reduce leukocyte adhesion in vivo. , 2000, International immunology.

[64]  Sofia Depner,et al.  Vascular endothelial growth factor‐induced skin carcinogenesis depends on recruitment and alternative activation of macrophages , 2012, The Journal of pathology.

[65]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[66]  D. Hanahan,et al.  Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.

[67]  Thomas Filleron,et al.  Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. , 2011, Cancer research.

[68]  M. Dimopoulos,et al.  VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2 , 2012, British Journal of Cancer.

[69]  G. Coukos,et al.  Targeting the tumor vasculature to enhance T cell activity , 2015, Current opinion in immunology.

[70]  Xiangxuan Zhao,et al.  Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells , 2016, Innate immunity.

[71]  D. Carbone,et al.  Differential Roles of Vascular Endothelial Growth Factor Receptors 1 and 2 in Dendritic Cell Differentiation1 , 2005, The Journal of Immunology.

[72]  D. Umetsu,et al.  Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen , 2001, Nature Immunology.

[73]  P. Clézardin.  Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. , 2011, Bone.

[74]  B. Rini,et al.  Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients , 2008, Clinical Cancer Research.

[75]  J. Girard,et al.  Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer , 2012, Oncoimmunology.

[76]  S. Du,et al.  Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis , 2017, Oncotarget.

[77]  M. O. oude Egbrink,et al.  Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. , 2003, Cancer research.

[78]  G. Giaccone,et al.  Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival , 2008, Clinical Cancer Research.

[79]  Jennie W. Taylor,et al.  Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. , 2013, Neuro-oncology.

[80]  L. Martiny,et al.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest , 2012, British journal of pharmacology.

[81]  Jonathan K. H. Tan,et al.  Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity , 2005, Journal of leukocyte biology.

[82]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[83]  J. Gamble,et al.  Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy. , 2017, Cancer research.

[84]  S. Mocellin,et al.  IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients1 , 2009, The Journal of Immunology.

[85]  E. Tartour,et al.  A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients , 2010, Journal of immunotherapy.

[86]  B. Rini,et al.  Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[87]  P. Rochaix,et al.  High endothelial venules (HEVs) in human melanoma lesions , 2012, Oncoimmunology.

[88]  Y. Kienast,et al.  Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade , 2017, Science Translational Medicine.

[89]  Helmut Kettenmann,et al.  The role of microglia and macrophages in glioma maintenance and progression , 2015, Nature Neuroscience.

[90]  W. Storkus,et al.  Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. , 2017, Advances in experimental medicine and biology.

[91]  G. Coukos,et al.  Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. , 2010, Current topics in microbiology and immunology.

[92]  A. Griffioen,et al.  Anti‐angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte‐endothelium interactions and infiltration in tumors , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[93]  D. Ribatti,et al.  Mast cells in breast cancer angiogenesis. , 2017, Critical reviews in oncology/hematology.

[94]  G. Foltz,et al.  VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. , 2015, Cancer letters.

[95]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[96]  C. Tinelli,et al.  Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer , 2011, Oncology.

[97]  D. Carbone,et al.  Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.

[98]  Jun Wang,et al.  Strategies targeting angiogenesis in advanced non-small cell lung cancer , 2017, Oncotarget.

[99]  K. Jooss,et al.  Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy , 2006, Clinical Cancer Research.

[100]  E. Tartour,et al.  Control of the Immune Response by Pro-Angiogenic Factors , 2014, Front. Oncol..

[101]  T. Daemen,et al.  Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication , 2015, Oncoimmunology.

[102]  I. Melero,et al.  Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes , 2009, British Journal of Cancer.

[103]  J. Werner,et al.  Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells , 2015, Oncoimmunology.

[104]  A. Zippelius,et al.  The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models , 2018, Cancer Immunology, Immunotherapy.

[105]  D. Carbone,et al.  Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. , 2007, Blood.

[106]  D. Lopez,et al.  The altered tumoricidal capacity of macrophages isolated from tumor- bearing mice is related to reduce expression of the inducible nitric oxide synthase gene , 1996, The Journal of experimental medicine.

[107]  I. Borrello,et al.  Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. , 2008, Cancer research.

[108]  Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B , 2017, Nature Communications.

[109]  Emma Gordon,et al.  Mechanisms and regulation of endothelial VEGF receptor signalling , 2016, Nature Reviews Molecular Cell Biology.

[110]  V. Koppaka,et al.  anti* , 2002, Annals of Internal Medicine.

[111]  M. Dimopoulos,et al.  VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2 , 2012, International journal of cancer.

[112]  Y. Thanavala,et al.  Importance of myeloid derived suppressor cells in cancer from a biomarker perspective. , 2020, Cellular immunology.